Ellerson Group Inc. ADV Has $3.85 Million Position in Pfizer Inc. (NYSE:PFE)

Ellerson Group Inc. ADV grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 833.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 133,572 shares of the biopharmaceutical company's stock after acquiring an additional 119,262 shares during the quarter. Pfizer accounts for approximately 3.3% of Ellerson Group Inc. ADV's holdings, making the stock its 11th largest holding. Ellerson Group Inc. ADV's holdings in Pfizer were worth $3,846,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its position in Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock worth $157,215,000 after buying an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC purchased a new position in shares of Pfizer during the fourth quarter worth $255,000. ETF Store Inc. lifted its position in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company's stock valued at $214,000 after purchasing an additional 727 shares during the period. KLCM Advisors Inc. boosted its holdings in Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company's stock valued at $5,004,000 after purchasing an additional 74,487 shares during the last quarter. Finally, Farmers Trust Co. grew its position in Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company's stock worth $6,503,000 after purchasing an additional 4,410 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday. Argus cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target on the stock. BMO Capital Markets reaffirmed an "outperform" rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $36.00.

Pfizer Trading Up 0.4 %

Pfizer stock traded up $0.11 during trading on Friday, reaching $27.81. 60,568,852 shares of the company were exchanged, compared to its average volume of 41,900,304. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock's 50 day simple moving average is $26.88 and its two-hundred day simple moving average is $28.21. The company has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a PEG ratio of 1.18 and a beta of 0.63. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm had revenue of $14.88 billion for the quarter, compared to analysts' expectations of $13.87 billion. During the same quarter in the previous year, the company posted $1.23 EPS. The company's revenue was down 19.5% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.36 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer's dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.